Literature DB >> 19433474

Beyond psychoanaleptics - can we improve antidepressant drug nomenclature?

D J Nutt.   

Abstract

Mesh：

Substances：

Year:  2009        PMID： 19433474     DOI： 10.1177/0269881109105498

Source DB:  PubMed          Journal:  J Psychopharmacol        ISSN： 0269-8811            Impact factor:   4.153


× No keyword cloud information.
  7 in total

1.  Progress on the Neuroscience-Based Nomenclature (NbN) for Psychotropic Medications.

Authors:  Pierre Blier; Maria A Oquendo; David J Kupfer
Journal:  Neuropsychopharmacology       Date:  2017-02-09       Impact factor: 7.853

2.  A multivariate approach linking reported side effects of clinical antidepressant and antipsychotic trials to in vitro binding affinities.

Authors:  Johanna Michl; Christian Scharinger; Miriam Zauner; Siegfried Kasper; Michael Freissmuth; Harald H Sitte; Gerhard F Ecker; Lukas Pezawas
Journal:  Eur Neuropsychopharmacol       Date:  2014-07-03       Impact factor: 4.600

Review 3.  Serotonergic modulation of glutamate neurotransmission as a strategy for treating depression and cognitive dysfunction.

Authors:  Alan L Pehrson; Connie Sanchez
Journal:  CNS Spectr       Date:  2013-08-01       Impact factor: 3.790

4.  A Neuroscience-Based Nomenclature (NbN) for Psychotropic Agents.

Authors:  Alan Frazer; Pierre Blier
Journal:  Int J Neuropsychopharmacol       Date:  2016-08-12       Impact factor: 5.176

5.  Creatine and taurine mixtures alleviate depressive-like behaviour in Drosophila melanogaster and mice via regulating Akt and ERK/BDNF pathways.

Authors:  Suhyeon Kim; Ki-Bae Hong; Singeun Kim; Hyung Joo Suh; Kyungae Jo
Journal:  Sci Rep       Date:  2020-07-09       Impact factor: 4.379

6.  Visualizing classification of drugs used in psychotic disorders: A 'subway map' representing mechanisms, established classes and informal categories.

Authors:  Crystal Zhou; David J Nutt; Simon Jc Davies
Journal:  J Psychopharmacol       Date:  2022-08-31       Impact factor: 4.562

7.  Multi-modality: a new approach for the treatment of major depressive disorder.

Authors:  Elliott Richelson
Journal:  Int J Neuropsychopharmacol       Date:  2013-01-30       Impact factor: 5.176
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.